Matthew Jarpe

TL;DR: In vivo and preclinical studies provide preclinical rationale for acetylated α-tubulin use as a pharmacodynamic biomarker in future clinical trials for HDAC6 inhibition in multiple myeloma.

TL;DR: Using motor neurons derived from induced pluripotent stem cells from patients with ALS and FUS mutations, the authors demonstrate that axonal transport deficits that are observed in these cells can be rescued by HDAC6 inhibition.

TL;DR: A novel mechanism in which the acetylation of tau on KXGS motifs inhibits phosphorylation on this same motif, and also prevents tau aggregation is described, uncovering a novel therapeutic pathway that can be manipulated to block the formation of pathogenic tau species in disease.

TL;DR: The results indicate that structure‐based computational design can be successfully applied to further improve the binding of high‐affinity antibodies and improve the single‐mutant success rate.

TL;DR: It is reported, for the first time to the authors' knowledge, that Cripto can directly bind to another TGF-beta ligand, Activin B, and thatCripto overexpression blocks ActivinB growth inhibition of breast cancer cells, suggesting a novel mechanism for antagonizing Activin signaling that could promote tumorigenesis by deregulating growth homeostasis.